Literature DB >> 20636664

Long-term outcomes in methamphetamine psychosis patients after first hospitalisation.

Phunnapa Kittirattanapaiboon1, Suwat Mahatnirunkul, Hathaichonnee Booncharoen, Pornthip Thummawomg, Unchalee Dumrongchai, Worawan Chutha.   

Abstract

INTRODUCTION AND AIMS: As a consequence of the methamphetamine epidemic in Thailand, the occurrence of methamphetamine psychosis (MAP) dramatically increased. This study aimed to examine the long-term outcomes of MAP patients following their first presentation to a psychiatric hospital. DESIGN AND METHODS: Methamphetamine psychosis patients who were first hospitalised in Suan Prung psychiatric hospital Thailand in 2000-2001 were identified through a review of the hospital database. Eligible participants were scheduled for visits by trained field researchers in 2007. For those giving consent, a structured face-to-face interview was conducted. Outcomes were collected from both medical records and interviews.
RESULTS: A total of 1116 participants were included in the study. Ninety-two (8.2%) participants had died from suicide, accident or AIDS. Due to relocation, only 449 (40.2%) individuals were interviewed. Most of the participants were male (90.6%) with a mean age of 33.3 years (SD = 8.0). The medical records showed that 263 had revisited the hospital in the interim. Of those, 39.2% were re-hospitalised and 38% were given a diagnosis of schizophrenia due to persistent psychosis. The outreach interview found that more than half (55.7%) had experienced psychosis relapse. Mini International Neuropsychiatric Interview revealed the following current conditions: psychotic disorders (15.8%), alcohol use disorders (52.1%) and suicidality (22.3%). Participants who did not have a diagnosis of current methamphetamine abuse could be divided into those with a single episode psychosis (52.6%) and those with chronic course of psychosis (38.8%). DISCUSSION AND
CONCLUSIONS: Individuals with MAP are likely to have poor outcomes, in terms of premature death, several relapses of psychotic symptoms, chronic psychotic manifestation, and very rates of alcohol use disorder and suicidality. Therefore, those individuals with MAP require long-term monitoring and psychiatric care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636664     DOI: 10.1111/j.1465-3362.2010.00196.x

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  25 in total

1.  Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis.

Authors:  Emily Stockings; Lucy Thi Tran; Thomas Santo; Amy Peacock; Sarah Larney; Damian Santomauro; Michael Farrell; Louisa Degenhardt
Journal:  Addiction       Date:  2019-07-28       Impact factor: 6.526

Review 2.  Methamphetamine psychosis: epidemiology and management.

Authors:  Suzette Glasner-Edwards; Larissa J Mooney
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

3.  Mortality, causes of death, and health status among methamphetamine users.

Authors:  Diane M Herbeck; Mary-Lynn Brecht; Katherine Lovinger
Journal:  J Addict Dis       Date:  2014-11-21

4.  Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Authors:  Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison
Journal:  Addiction       Date:  2014-03-17       Impact factor: 6.526

5.  Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.

Authors:  Kenneth S Kendler; Henrik Ohlsson; Jan Sundquist; Kristina Sundquist
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

Review 6.  Suicide Rates After Discharge From Psychiatric Facilities: A Systematic Review and Meta-analysis.

Authors:  Daniel Thomas Chung; Christopher James Ryan; Dusan Hadzi-Pavlovic; Swaran Preet Singh; Clive Stanton; Matthew Michael Large
Journal:  JAMA Psychiatry       Date:  2017-07-01       Impact factor: 21.596

7.  Methamphetamine enhances the development of schizophrenia in first-degree relatives of patients with schizophrenia.

Authors:  Huabing Li; Qiong Lu; Enhua Xiao; Qiuyun Li; Zhong He; Xilong Mei
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

8.  Long-term follow-up of patients treated for psychotic symptoms that persist after stopping illicit drug use.

Authors:  Xianhua Deng; Zhibiao Huang; Xuewu Li; Yi Li; Yi Wang; Dongling Wu; Beiling Gao; Xi Yang
Journal:  Shanghai Arch Psychiatry       Date:  2012-10

Review 9.  Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?

Authors:  Jørgen G Bramness; Øystein Hoel Gundersen; Joar Guterstam; Eline Borger Rognli; Maija Konstenius; Else-Marie Løberg; Sigrid Medhus; Lars Tanum; Johan Franck
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

Review 10.  The neurobiology of methamphetamine induced psychosis.

Authors:  Jennifer H Hsieh; Dan J Stein; Fleur M Howells
Journal:  Front Hum Neurosci       Date:  2014-07-22       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.